Skip to content
Governance Register

← US public companies

Aclaris Therapeutics, Inc.

SEC CIK 1557746 · ACRS · last insider filing 2026-06-08

Directors (from insider filings)

NameCapacity as filedFilings
Schiff Andrew N Director filed 2017 - 2026
Milano Vincent Director filed 2020 - 2026
Gowen Maxine Director filed 2019 - 2026
Mehra Anand Director filed 2015 - 2026
Molineaux Christopher P. Director filed 2015 - 2026
Humphries William D. Director filed 2016 - 2026
Walker Neal Director · President and CEO filed 2015 - 2026
Davis Hugh M. Director · President and COO filed 2024 - 2026
Powell Andrew Kenneth William Director filed 2017 - 2024
Reasons Bryan M. Director filed 2018 - 2024
Manion Douglas J. Director · Pres and COO filed 2022 - 2024
Tullman Stephen A. Director filed 2015 - 2018
Bierly Rick Director filed 2015 - 2017
Cha Albert Director filed 2015 - 2016

Officers (from insider filings)

NameTitle as filedFilings
Hall Jesse Wayne Chief Medical Officer filed 2025 - 2026
Balthaser Kevin Chief Financial Officer filed 2023 - 2026
Loerop James Chief Business Officer filed 2022 - 2026
Kolbeck Roland Wilhelm Chief Scientific Officer filed 2025 - 2026
Monahan Joseph Chief Scientific Officer filed 2021 - 2025
Cawkwell Gail Chief Medical Officer filed 2022 - 2023
Ruffo Frank Chief Financial Officer filed 2015 - 2022
Ali-Jackson Kamil Chief Legal Officer filed 2015 - 2022
Gordon David N. Chief Medical Officer filed 2018 - 2021
Shanler Stuart Chief Scientific Officer filed 2015 - 2019
Powala Christopher Chief Reg & Develop Officer filed 2015 - 2019
Fair Brett Chief Commercial Officer filed 2018 - 2019

About this record

From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.

Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.